The prognosis in metastatic patients can be assessed based on a system developed by The International Germ Cell Cancer Collaborative Group, which includes location of metastases and serum levels of three testicular cancer biomarkers: alpha-fetoprotein, human chorionic gonadotrophin, lactate dehydrogenase. This evidence concerns the gene AFP and malignant germ cell tumor.